HOOKIPA Pharma Inc.

0.70 USD
-0.01 (-0.85%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

HOOKIPA Pharma Inc. stock is down -18.58% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 16.67% of the previous 5 June’s closed higher than May. 100% of analysts rate it a buy.

About HOOKIPA Pharma Inc.

HOOKIPA Pharma Inc. develops immunotherapeutics targeting infectious diseases and cancers. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers.

  • HC Wainwright & Co.
    Wed Jun 5, 07:37
  • RBC Capital
    Tue May 21, 13:09